Clinical trials: Diarrhea Predominant Irritable Bowel Syndrome
- Condition Diarrhea Predominant Irritable Bowel Syndrome
- Funder type Industry (pharma, biotech, devices)
Diarrhea-predominant Irritable Bowel Syndrome
Treatment of Diarrhea-predominant Irritable Bowel Syndrome (IBS-D) With LACTEOL® 340 mg
Irritable bowel syndrome is a complex condition with a high unmet medical need for effective and safe treatment options. Lacteol® is a lactobacillus product used for adjunctive and symptomatic treatment of diarrhea.
- Trial name
- NCT01358708
- Testing
- LACTEOL® 340 mg
- Where
- 8 sites in France, Germany
- Volunteers
- 26 people
- Sponsor
- Forest Laboratories
Irritable Bowel Syndrome
A Study of 3 Doses of Dextofisopam in Females With Irritable Bowel Syndrome
The primary objectives of this study are to evaluate the clinical safety and tolerability and to assess the efficacy of 100 mg, 200 mg, and 300 mg BID dextofisopam compared with placebo in female outpatients with…
- Trial name
- NCT00486876
- Testing
- Dextofisopam
- Where
- 79 sites in United States
- Volunteers
- 324 people
- Sponsor
- Pharmos
Diarrhea-Predominant Irritable Bowel Syndrome
Study to Assess Effects of Postbiotic vs Placebo in Participants With Diarrhea-predominant IBS
The present study is a randomized, double-blind, placebo-controlled, parallel group clinical study that assesses the effect of postbioc on the complaints of subjects with moderate to severe diarrhoea-predominant irritable bowel…
- Trial name
- NCT06346847
- Testing
- Postbiotic
- Where
- 23 sites in India
- Volunteers
- 384 people, healthy volunteers welcome
- Sponsor
- A-Mansia Biotech S.A.
Irritable Bowel Syndrome
A Study to Evaluate Efficacy of YM060 on Diarrhea-predominant Irritable Bowel Syndrome (D-IBS) in Female Patients
A study to verify the superiority of YM060 (ramosetron) to placebo for female patients with diarrhea-predominant irritable bowel syndrome (D-IBS) and to evaluate its safety.
- Trial name
- NCT01274000
- Testing
- YM060
- Where
- 4 sites in Japan
- Volunteers
- 409 people
- Sponsor
- Astellas Pharma Inc
Irritable Bowel Syndrome With Diarrhea
Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of BEKINDA (Ondansetron 12 mg Bimodal Release Tablets) for Diarrhea Predominant Irritable Bowel Syndrome (IBS-D)
This is a randomized, double-blind, placebo-controlled, 2-arm parallel group study. After qualifying for the study and signing informed consent, patients will undergo a two-week observation period during which stool consistency…
- Trial name
- NCT02757105
- Testing
- BEKINDA
- Where
- 16 sites in United States
- Volunteers
- 127 people
- Sponsor
- RedHill Biopharma Limited
Irritable Bowel Syndrome
Olorinab in Irritable Bowel Syndrome With Predominant Constipation (IBS-C) and Irritable Bowel Syndrome With Predominant Diarrhea (IBS-D)
The purpose of this study is to determine whether olorinab is a safe and effective treatment for abdominal pain in participants with irritable bowel syndrome (IBS).
- Trial name
- CAPTIVATE (NCT04043455)
- Testing
- Olorinab
- Where
- 69 sites in United States
- Volunteers
- 273 people
- Sponsor
- Arena Pharmaceuticals
Diarrhea-predominant Irritable Bowel Syndrome
A Long Term Study of YM060 in Female Patients With Diarrhea-predominant Irritable Bowel Syndrome
To evaluate the efficacy and safety of YM060 once daily for female patients with diarrhea-predominant irritable bowel syndrome (D-IBS) for a long-term period (up to 52 weeks).
- Trial name
- NCT01736423
- Testing
- YM060
- Where
- 4 sites in Japan
- Volunteers
- 151 people
- Sponsor
- Astellas Pharma Inc
Irritable Bowel Syndrome
A Study of YM060 in Diarrhea-predominant Irritable Bowel Syndrome (d-IBS)
This study will examine the efficacy, safety and tolerability of different oral dose of YM060, 5-HT3 receptor antagonist, in patients with d-IBS.
- Trial name
- NCT00189813
- Testing
- YM060
- Where
- 45 sites in Bulgaria, Czechia and 6 more
- Volunteers
- 691 people
- Sponsor
- Astellas Pharma Inc
Irritable Bowel Syndrome
Phase 3 Study of YM060 in Patients With Diarrhea-predominant Irritable Bowel Syndrome (d-IBS)
This study will examine the efficacy, safety and tolerability of oral dose of YM060, 5-HT3 receptor antagonist, in patients with d-IBS.
- Trial name
- NCT00189696
- Testing
- YM060
- Where
- 4 sites in Japan
- Sponsor
- Astellas Pharma Inc
Irritable Colon
Safety and Efficacy Study of GR68755 (Alosetron Hydrochloride) to Treat Severe Diarrhea-Predominant Irritable Bowel Syndrome (IBS)
This study is an exploratory study aiming (i) to obtain clinical experience of GR68755 in Japanese subjects with severe d-IBS to explore the feasibility of the next phase study and (ii) to obtain reference data for endpoints and…
- Trial name
- NCT01855711
- Testing
- GR68755 (Alosetron hydrochloride) 1 mg tablet
- Volunteers
- 32 people
- Sponsor
- GlaxoSmithKline
Irritable Bowel Syndrome With Diarrhea
The Efficacy of PX0612 In The Treatment Of Irritable Bowel Syndrome
IBS is a disorder of movement in the gut. People who have IBS may have diarrhea, constipation, or alternating bouts of both. IBS is not caused by injury or illness.
- Trial name
- NCT02431533
- Testing
- PX0612, Di-Calcium Phosphate
- Where
- Canada
- Volunteers
- 50 people
- Sponsor
- Pharmabiotix Inc
Irritable Bowel Syndrome, Colonic Diseases
A Study of Crofelemer to Treat Diarrhea Irritable Bowel Syndrome
This study is designed to evaluate the safety and effectiveness of an investigational drug, TRN-002 (crofelemer) to relieve the symptoms of diarrhea-predominant irritable bowel syndrome (IBS).
- Conditions
- Irritable Bowel Syndrome, Colonic Diseases, Diarrhea, Gastrointestinal Disease
- Trial name
- NCT00101725
- Testing
- crofelemer
- Where
- 29 sites in United States
- Volunteers
- 245 people
- Sponsor
- Bausch Health Americas, Inc.
Irritable Bowel Syndrome (IBS)
Study to Evaluate the Effects of ONO-2952 on Pain Perception Produced by Rectal Distention in Female Subjects With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)
The objective is to evaluate whether ONO-2952 modulates visceral pain perception produced by rectal distention in female patients with IBS-D
- Trial name
- RESTORE (NCT01887002)
- Testing
- ONO-2952
- Where
- 4 sites in United States
- Volunteers
- 39 people
- Sponsor
- Ono Pharma USA Inc
Irritable Bowel Syndrome
Efficacy, Safety, and Tolerability of Eluxadoline in the Treatment of Participants With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-d)
The purpose of this study is to determine the efficacy, safety, and tolerability of different doses of eluxadoline (JNJ-27018966) compared with placebo in the treatment of participants with diarrhea-predominant irritable bowel…
- Trial name
- NCT01553747
- Testing
- Eluxadoline
- Where
- 253 sites in United States, Canada and 2 more
- Volunteers
- 1,146 people
- Sponsor
- Furiex Pharmaceuticals, Inc
Irritable Bowel Syndrome (IBS), Irritable Bowel Syndrome of Diarrhea Type (IBS-D)
Gelsectan® in the Treatment of Patients With Diarrhoea-predominant Irritable Bowel Syndrome
Irritable Bowel Syndrome (IBS) is one of the major Disorders of Gut-Brain Interaction (DGBI) and the most frequent reasons for referral to both primary care providers and gastroenterologists.IBS is not a life-threatening disease…
- Trial name
- GIANT (NCT06681012)
- Testing
- Gelsectan®
- Where
- 12 sites in Belgium, France and 2 more
- Volunteers
- 330 people
- Sponsor
- Devintec Sagl
Diarrhea-predominant Irritable Bowel Syndrome
Study to Evaluate the Efficacy, Safety, and Tolerability of BOS-589 in the Treatment of Patients With Diarrhea-predominant Irritable Bowel Syndrome (IBS-D)
This study is being conducted to evaluate in participants with diarrhea-predominant Irritable Bowel Syndrome (IBS-D) the abdominal pain response to BOS-589 after 4 weeks of treatment and to evaluate the overall safety and…
- Trial name
- NCT03977155
- Testing
- BOS-589
- Where
- 58 sites in United States
- Volunteers
- 133 people
- Sponsor
- Boston Pharmaceuticals
Diarrhea Predominant Irritable Bowel Syndrome
Lactibiane Tolérance® in Individuals Suffering From Irritable Bowel Syndrome With Diarrheal Predominance
The main objective of the study is to evaluate the effect on intestinal permeability of a supplementation with Lactibiane Tolérance® for 4 weeks (28 days) in patients suffering from irritable bowel syndrome (IBS) with diarrhea…
- Trial name
- PILATE (NCT02728063)
- Testing
- Lactibiane Tolerance
- Where
- France
- Volunteers
- 30 people
- Sponsor
- PiLeJe
Irritable Colon
Study to Assess the Effect Of Alosetron On Mucosal Blood Flow
This study will look at colonic mucosal blood flow in subjects who have taken alosetron vs placebo and healthy volunteers vs diarrhea-predominant Irritable Bowel Syndrome (d-IBS) patients.
- Trial name
- NCT00370032
- Testing
- alosetron
- Where
- United Kingdom
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Irritable Bowel Syndrome With Diarrhea, Irritable Bowel Syndrome
Safety and Efficacy of a Probiotic Supplement in IBS-D
This study aims to assess the safety and efficacy of a single probiotic strain on symptom severity in adults with diarrhea-predominant Irritable Bowel Syndrome (IBS-D).
- Trial name
- IBIS (NCT05754177)
- Testing
- Probiotic
- Where
- Slovenia
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- The Archer-Daniels-Midland Company
Irritable Bowel Syndrome With Diarrhea
Evaluating the Safety and Efficacy of the Probiotic Bifidobacterium Longum ES1 and the Post Biotic Heat-treated Bifidobacterium Longum ES1 (HT-ES1) on IBS Symptom Severity in Patients With Diarrhoea Predominant Irritable Bowel Syndrome
Randomized controlled clinical study has been proposed to evaluate the safety and efficacy of ES1 probiotic strain and heat-treated ES1 postbiotic strain in individuals suffering from IBS-D.
- Trial name
- NCT05339243
- Testing
- ES 1, HT ES1
- Where
- 8 sites in India
- Volunteers
- 200 people
- Sponsor
- Vedic Lifesciences Pvt. Ltd.